Recursion Pharmaceuticals
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
126 of 143
Related slides by other companies
MaxCyte
Investor Presentation
January 2024
enabled active clinical trials | MaxCyte
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned to expand best combination arms | MAIA Biotechnology
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
Allarity Therapeutics
Investor Conference
September 2022
platform extensively studied in clinical trials | Allarity Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io